MedTrace Logo

Multiple Ascending Dose Study of BMS-929075 in Hepatitis C Virus (HCV) Infected Patients

NCT01525212 · Status: WITHDRAWN · Phase: PHASE1 · Type: INTERVENTIONAL

Last updated 2013-06-21

No results posted yet for this study

Summary

The purpose of this study is to determine the change from baseline in HCV Ribonucleic acid (RNA) on Day 4 following three days of dosing with BMS-929075 in chronically genotype subtype 1a and 1b HCV infected subjects

Conditions

  • Chronic Hepatitis C

Interventions

DRUG

BMS-929075

Oral Suspension, ≤ 25 mg, Once daily, 3 days

DRUG

BMS-929075

Oral Suspension, ≤ 100 mg, Once daily, 3 days

DRUG

BMS-929075

Oral Suspension, ≤ 400 mg, Once daily, 3 days

DRUG

BMS-929075

Oral Suspension, (≤ 800 mg, Once daily) OR (≤ 400 mg, Twice daily), 3 days

DRUG

Placebo matching BMS-929075

Oral Suspension, 0 mg, Once daily, 3 days

DRUG

Placebo matching BMS-929075

Oral Suspension, 0 mg, (Once daily for ≤ 800 mg group) OR (Twice daily for ≤ 400 mg group), 3 days

Sponsors & Collaborators

Principal Investigators

  • Bristol-Myers Squibb · Bristol-Myers Squibb

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-04-30
Primary Completion
2013-02-28
Completion
2013-02-28

Countries

  • Australia

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01525212 on ClinicalTrials.gov